Also this week, Eli Lilly released the long-awaited results on its new Alzheimer’s drug, donanemab. Although they weren’t conclusive, the company is saying it did show slowing of cognitive and functional decline. In early-stage patients, those who took the drug had a better composite score for cognition and the ability to perform the activities of daily living than those who received the placebo.
Read the New England Journal of Medicine summary.